Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bulbixin is a patented nanocarrier delivery technology developed by the Italian biotech company iDelivery i.S.r.l. It is specifically engineered to facilitate transfollicular topical delivery, allowing active compounds to bypass the skin's primary barriers and reach the pilosebaceous unit, which includes the hair follicle and sebaceous gland. As a versatile delivery platform, Bulbixin can be loaded with various active ingredients to target conditions such as androgenetic alopecia (hair loss), unwanted hair growth (hair removal), and acne. The technology focuses on optimizing the penetration and localized delivery of therapeutic or cosmetic agents directly to the hair bulb and associated structures, enhancing their efficacy compared to standard topical formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bulbixin.